One of the biggest game-changing advancements in cancer care came about 20 years ago when researchers learned that they could create medicines that selectively jam up cancer’s growth machinery without damaging the rest of the body. Today these medicines, called targeted therapies, are available for treating many forms of cancer.

Targeted therapies took center stage when Alice Shaw started her career as a physician-scientist caring for patients with lung cancer. Now, as Global Head of Translational Clinical Oncology at the Novartis Institutes for BioMedical Research (NIBR), Shaw aims …

  • Novartis worked with the EMA to update the Beovu® (brolucizumab) label to guide physicians in their treatment of wet AMD  
  • The update includes the additional characterization of retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation1
  • Novartis has established a multidisciplinary panel of internal experts collaborating with external advisors to examine the root cause, potential risk factors and mitigation of these adverse events
  • In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1
  • In a key secondary endpoint, more than half of Beovu patients were maintained on a three-month dosing interval through year one, following the loading phase1
  • Beovu showed superior improvement versus aflibercept in change of central subfield thickness, a secondary endpoint, over the period of week 40 through week 521